The latest research study “Alpha Emitter Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” by IMARC Group, finds that the global alpha emitter market size reached US$ 1,150.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 5,929.6 Million by 2028, exhibiting a growth rate (CAGR) of 28.37% during 2023-2028.
Alpha emitters refer to substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to gain effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. As a result, they cause less damage to adjacent normal tissues. Radium, lead, and bismuth are some of the radionuclides utilized in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, melanoma, etc.
Request a free sample brochure: https://www.imarcgroup.com/alpha-emitter-market/requestsample
Alpha Emitter Market Trends and Drivers:
The elevating investments in R&D activities for cancer treatment are primarily augmenting the alpha emitter market. Furthermore, the rising consumer awareness towards the cell-killing abilities of targeted substances is positively influencing the global market. Apart from this, the growing prevalence of several types of cancer among individuals is acting as another significant growth-inducing factor. Moreover, the expanding geriatric population who are more susceptible to developing various cardiac ailments is also bolstering the market growth. Besides this, the widespread adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is further catalyzing the global market. Additionally, numerous technological advancements and the increasing number of new nuclear-medicine-based product approvals are expected to fuel the alpha emitter market in the coming years.
Alpha Emitter Market Report Segmentation 2023-2028:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.
The report has been segmented the market into following categories:
Breakup by Type of Radionuclide:
Breakup by Medical Application:
- Prostate Cancer
- Bone Metastasis
- Ovarian Cancer
- Pancreatic Cancer
- Endocrine Tumors
Breakup by End User:
- Medical Research Institutions
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Key highlights of the report:
• Market Performance
• Market Outlook
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800